PCSA

$3.16

Post-MarketAs of Mar 17, 8:00 PM UTC

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment.

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

MT Newswires
Dec 18, 2025

Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline

US stocks look set to open higher in Thursday's trading session as investors dissect key inflation a

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
MT Newswires
Dec 17, 2025

Top Midday Gainers

Processa Pharmaceuticals (PCSA) said Wednesday that an update from its phase 2 study of a combinatio

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Dec 17, 2025

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Aug 6, 2025

Insider Stock Buyers At Processa Pharmaceuticals Recouped Some Losses This Week

Insiders who bought US$213.4k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) stock in the last year recovered...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Jul 11, 2025

Processa Pharmaceuticals, Inc. (PCSA) Secures Buy Rating on Portfolio Progress

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is among the fundamentally strong penny stocks to invest in. Analysts at H.C. Wainwright have reiterated their Buy rating on Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) while maintaining a price target of $2, implying an upside of over 900%. This overwhelming optimism stems from the company’s comprehensive portfolio update just a few days […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.